Lupin and Natco Pharma have received U.S. FDA approval for their generic Eribulin Mesylate Injection, bioequivalent to Eisai’s Halaven®, expanding access to cost-effective treatments for metastatic breast cancer and liposarcoma in the United States.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Lupin Limited and its alliance partner Natco Pharma have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. The product is bioequivalent to Halaven® (eribulin mesylate) Injection, marketed by Eisai, and represents a significant expansion of affordable oncology treatment options in the United States.
Clinical Indications
Eribulin Mesylate Injection is indicated for adults with metastatic breast cancer who have previously received at least two chemotherapy regimens for metastatic disease. It is also approved for patients with unresectable or metastatic liposarcoma who have undergone prior anthracycline-containing treatment. Both conditions remain difficult to manage, underscoring the importance of accessible, cost-effective therapies.
Market Impact
According to IQVIA data, Halaven® recorded estimated annual U.S. sales of USD 43.7 million for the 12 months ending April 2026. The introduction of a generic alternative is expected to reduce treatment costs and broaden patient access. With Halaven® currently the only eribulin product available in the U.S. The generic launch is expected to increase treatment accessibility and provide a lower-cost alternative for eligible patients
Strategic Significance
This approval highlights the strength of the Lupin–Natco partnership, which has consistently focused on bringing complex generics to market. Both companies have emphasized their FDA-compliant manufacturing capabilities and track record in sterile injectables, reinforcing confidence in product quality and supply reliability. The approval further expands the oncology portfolios of both companies and reflects their ongoing commitment to developing and commercializing complex generic medicines for patients worldwide.
Path Forward
Launch details for the U.S. market are expected to follow. The availability of generic eribulin mesylate is anticipated to support oncologists and healthcare providers in delivering more affordable care for patients with advanced breast cancer and liposarcoma. As demand for cost-effective cancer therapies continues to rise, Lupin and Natco’s latest approval underscores their commitment to expanding treatment access worldwide.
References
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.
